Results 271 to 280 of about 268,104 (311)
Some of the next articles are maybe not open access.
Acta Ophthalmologica, 2012
AbstractPurpose To assess safety and efficacy of intraocular injections of anti‐VEGF in patients with diabetic macular edema (DME)Methods The gold standard for treatment has been laser coagulation. Limitations of this therapy are refractive DME, ischemic diabetic maculopathy and complications after laser application.
openaire +1 more source
AbstractPurpose To assess safety and efficacy of intraocular injections of anti‐VEGF in patients with diabetic macular edema (DME)Methods The gold standard for treatment has been laser coagulation. Limitations of this therapy are refractive DME, ischemic diabetic maculopathy and complications after laser application.
openaire +1 more source
Anti-VEGF therapy in pituitary carcinoma
Pituitary, 2011We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide administration, anti-VEGF therapy was begun. MRI, PET scan and pathologic analysis were undertaken.
Ortiz, Leon D. +8 more
openaire +3 more sources
Intravitreal Anti-VEGF Therapy for Retinal Macroaneurysm
Klinische Monatsblätter für Augenheilkunde, 2013We evaluated the effect of intravitreal anti-vascular endothelial growth factor therapy using bevacizumab or ranibizumab for retinal macroaneurysms with macular exudation.In a retrospective interventional case series patients with retinal macroaneurysms were treated with either 1.25 mg intravitreal bevacizumab or 0.5 mg ranibizumab as first-line ...
Zweifel, S A +4 more
openaire +2 more sources
New Anti-VEGF Drugs in Ophthalmology
Current Drug Targets, 2020: This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. : Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
openaire +2 more sources
Antiangiogenesis, Anti-VEGF(R) and Outlook
2007Tumor angiogenesis and antiangiogenesis has moved from an exotic research topic into clinical practice defining a new and promising avenue of targeted cancer therapy. Starting with a historical perspective on tumor angiogenesis, this review provides the basic concepts and classification of angiogenesis inhibition.
openaire +2 more sources
Endophthalmitis After Anti-VEGF Injections
Ophthalmology, 2009Kathryn S, Klein +7 more
openaire +2 more sources
Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?
Lancet, The, 2022Pearse A Keane, Mark A Chia Mbbs Mmed
exaly

